With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
In an interim analysis, the stent appeared to reduce revascularization rates and improve Rutherford score, walk distance, and walk score. A randomized trial completed enrollment last year.
Provided operators have the training and experience, there's no reason STEMI patients can't be treated via a transradial approach, and there may even be advantages to doing so, several reports suggest.
Results are early and in limited numbers, but experts say the Coherex FlatStent, deployed just in the area of overlap between the septum primum and the septum secundum, is a promising new addition to the field.
A unique strategy of "repatriating" stable STEMI patients back to their referring hospitals post-PCI has no downside in terms of mortality and may help hospitals improve door-to-balloon times, clear out their PCI wards, and share the burden—and rewards—of patient care.
The device can be deployed within 60 minutes and appears to be a safe and effective option for patients with mitral-valve regurgitation too sick for open-heart procedures, results from the 30-patient trial show.
The regional study highlights the need for studies addressing whether stent-thrombosis-STEMI patients should be treated the same as other STEMI patients.
UPDATED // One-year risk of cardiovascular events is 50% higher in patients taking a proton-pump inhibitor on top of clopidogrel and similar for four PPIs, according to a retrospective cohort study of more than 16 700 patients who received clopidogrel poststenting.
Provided operators have the training and experience, there's no reason STEMI patients can't be treated via a transradial approach, and there may even be advantages to doing so, several reports suggest.
